Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
28 Februar 2023 - 2:00PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs, today published its 2022 Environmental, Social and
Governance (ESG) Report, the first time the company has reported on
its sustainability efforts in these areas.
“I am pleased to share our 2022 Ardelyx ESG report, which
showcases the ways we have invested in our patients, employees and
the communities we serve, to build a more equitable and sustainable
society,” said Mike Raab, president and chief executive officer of
Ardelyx. “In recent years, we have proven our resilience as a
company, as a society and as individuals, and all of us at Ardelyx
are committed to continuing to adapt and grow. While we are still
early in our ESG journey, I am proud of the foundation and culture
within Ardelyx that embraces social consciousness and
sustainability. We look forward to continuing to work with our
stakeholders, with a priority towards the patients we seek to
serve, to shape a better future for all.”
Highlights from Ardelyx’s ESG activities in 2022 include:
- Created ArdelyxAssist™, a patient services program designed to
provide a broad range of access and affordability support for
patients and health care providers
- Donated more than $2 million to support educational programs
for healthcare providers, patients and caregivers
- Donated more than eleven pallets and six truckloads of R&D
supplies and equipment to non-profit STEM organizations
- Sponsored the California Life Sciences Association Racial and
Social Equity Initiative, a first step in a unified effort for the
life sciences industry in California to do more for the
under-served and under-represented
- Named one of the “Deloitte Technology Fast 500™,” a ranking of
the 500 fastest-growing technology, media, telecommunications, life
sciences, fintech and energy tech companies in North America
The ESG report details areas of the company’s ESG focus,
including patient access and affordability; product quality
management and safety; clinical study standards; patient advocacy
and corporate giving; training and development; diversity, equity
and inclusion; employee health, safety and wellness; COVID-19
response; governance and leadership; business ethics and
compliance; ethical marketing; and data privacy. The comprehensive
report can be found here.
About Ardelyx, Inc.Ardelyx was founded with a
mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs.
Ardelyx’s first approved product, IBSRELA® (tenapanor) is available
in the United States and Canada. Ardelyx is developing XPHOZAH®
(tenapanor), a novel product candidate for the control of serum
phosphorus in adult patients with chronic kidney disease (CKD) on
dialysis, which has completed three successful Phase 3 trials.
Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the
potential treatment of elevated serum potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease and
an early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established agreements
with Kyowa Kirin in Japan, Fosun Pharma in China and Knight
Therapeutics in Canada for the development and commercialization of
tenapanor in their respective territories. For more information,
please visit https://ardelyx.com/ and connect with us on Twitter,
LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Kimia Keshtbod kkeshtbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024